Late Cystic Metastasis of an Ovarian Granulosa Cell Tumor to the Liver

Ammar Aleter 1, Parag S. Mahajan 2, Mahir A. Petkar 3, Hatem A. Abdulmajeed 2, Hatem Khalaf 1, 4, Walid Elmoghazy 1, Ahmed Elaffandi 1

1. Department of Surgery, Hamad Medical Corporation, Doha, Qatar 2. Department of Clinical Imaging, Hamad Medical Corporation, Doha, Qatar 3. Department of Apheresis & Hemovigilance, Hamad Medical Corporation, Doha, Qatar 4. College of Medicine, Qatar University, Doha, Qatar

Corresponding author: Ammar Aleter, aaleter@hamad.qa

Abstract

Granulosa cell tumor (GCT) is a unique form of sex cord tumor that is mostly unilateral and of low-grade malignancy. Most GCT recurrence is with pelvic or peritoneal dissemination. Liver metastasis is rarely reported. This study reports a rare case of GCT with liver metastasis nine years post initial presentation. We also discuss surgical intervention, radiological findings, histology, treatment approaches, and review of similar reported cases.

Categories: Pathology, Radiology, General Surgery
Keywords: sex cord stromal tumors, granulosa cell tumor, liver metastasis, late recurrence, partial hepatectomy

Introduction

The World Health Organization’s histological classification of ovarian tumors in 2014 defined granulosa cell tumor (GCT) as a subtype of sex cord-stromal tumor. These tumors are low-grade malignant tumors, which consist of pure sex cord tumors and pure stromal tumors [1]. The GCT is a rare type of tumor and is considered a pure stromal tumor, accounting for 2-5% of ovarian tumors and 70% of sex cord-stromal tumors [2]. It is divided into adult GCTs, which is the most common with an incidence of 95%, and juvenile GCTs [2]. GCT is typically treated by ovariectomy and has a good prognosis in general; nevertheless, late recurrence can be found. GCT metastasis and recurrence are often encountered with pelvic or peritoneal dissemination, whereas distant metastases to the lung, brain, and liver are less common [3]. Liver metastasis was noted only in 5-6% of the cases [3].

Ovarian GCT with liver metastasis is seldom documented, and liver metastasis can be easily misdiagnosed as a mucinous cystadenoma or primary liver cancer. For which, surgical removal may not be performed, leading to a deteriorative pathogenetic condition [4]. Resection of liver metastases for GCTs is frequently performed as a palliative rather than a therapeutic procedure; however, in many cases, it may improve the quality of life significantly [4].

This study reports with a literature review the case of a patient in whom primary GCT of the ovary was diagnosed more than nine years prior to liver metastatic resection.

Our case is unique, as it was radiologically evaluated by ultrasonography (US), computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, and fluoro-deoxy glucose positron emission tomography (FDG-PET) CT scan, and the diagnosis of delayed hepatic metastatic recurrence was suspected preoperatively on MRI and PET-CT. The diagnosis of hepatic metastasis from GCT was strongly considered on the MRI scan due to the clinical history and some similarities in the appearance of the hepatic metastasis with the primary GCT of the ovary on the preoperative pelvic MRI done nine years ago. Also, the hepatic lesion showed low-level FDG uptake on PET-CT that is typical of ovarian GCTs.

Case Presentation

This patient is a 56-year-old lady who presented to the emergency department on November 27, 2020, regarding on and off severe epigastric pain radiating to her back for one month associated with nausea. The patient did not report any feeling of abdominal mass, and she did not have any weight or appetite loss during the past months. She is post-menopausal with no complaint of vaginal bleeding, discharge, or lower abdominal pain. There were no other gastrointestinal or urologic symptoms, and her systemic review was unremarkable. Her past surgical history is significant for an open surgical intervention done due to a right ovarian tumor diagnosed in March 2012. The surgical intervention was cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, ascites cytology, bilateral pelvic lymph node dissection, para-aortic lymph node sampling, and omental biopsy. Her final histopathology diagnosis came as an adult-type granulosa cell tumor of the right ovary stage III-A.
The patient received adjuvant chemotherapy starting from May up to September 2012 composed of bleomycin, etoposide, cisplatin (BEP) protocol for one cycle; however, the protocol was shifted to paclitaxel and carboplatin due to severe neutropenia and gastrointestinal discomfort. The patient received six cycles of the second protocol with no significant side effects. She was followed closely for five years in the clinic, up to 2017, by physical examinations and scheduled imaging with no signs of recurrence and was then lost to further follow-up. Her family history is positive for breast cancer in her cousin and lung cancer in her father, and she also had multiple comorbidities, including diabetes mellitus type two, gastritis, and benign thyroid nodules.

On examination in the emergency department in November 2020 (nine years later), the patient was found to have mild tenderness in the epigastric area, no guarding or rigidity, and no masses or hernias could be felt. All her laboratory results, including complete blood count (CBC), liver enzymes, hepatitis serology, tumor markers, such as AFP (alpha-fetoprotein), CA19-9 (carbohydrate antigen 19-9), CA 125 (cancer antigen 125), CA 15-3 (cancer antigen 15-3), and estradiol, were within the normal range. Anti-Müllerian hormone (AMH), which is considered currently by many authors as an efficient hormone for the diagnosis and follow-up of granulosa cell tumors, was within the normal range as well [5]. On the other hand, her inhibin-B value, which is another tumor marker, proved to be efficient in detecting both primary and recurrent disease was elevated (120 PG/ML) [6-7]. The US done at presentation showed an ill-defined, mixed, echogenic, predominantly hypoechoic focal lesion with posterior acoustic enhancement and irregular margins measuring 5.7 x 6.6 x 5.3 cm in the left lobe of the liver (Figure 1). No obvious vascularity was noted within the lesion with minimal peripheral and septal vascularity. Features suggested a complex cystic lesion. CT scan with intravenous (IV) contrast confirmed the US findings (Figure 2).

FIGURE 1: Liver ultrasound showing a complex cystic mass lesion with vascularity in the wall and the septae
FIGURE 2: Post-contrast (venous phase) CT scan of the liver showing a complex cystic mass lesion in the left lobe of the liver with an enhancement of the wall and the septae

MRI done to further delineate the lesion showed a well-defined, well-encapsulated, rounded, multilocular, septated, and complex cystic lesion in the left lobe of the liver (segments III, IVb) (Figure 3). It measured approximately 7.9 x 6.8 x 7.8 cm. It was heterogeneously hyperintense on both T1 and T2-weighted images with hypointense capsule and septa on both sequences. It showed fluid-debris levels within likely, suggestive of chronic hemorrhage/highly proteinaceous content. There were enhancing nodular and papillary projections with diffusion restriction in the soft tissue nodules, suspicious of malignant transformation. The lesion was seen stretching the liver capsule, abutting the pyloric region of the stomach, the duodenal bulb, the junction between the head and body of the pancreas, and the main portal vein; otherwise, the liver was normal in signal intensity and enhancement pattern. In the arterial phase, there was no appreciable enhancement, and in the venous and delayed phases, it showed enhancement of the capsule and the internal septa and no appreciable enhancement of the rest of the lesion. There was mild hepatomegaly; otherwise, the rest of the liver was normal. Preoperative MRI of pelvis done in 2012 was available for comparison (Figure 4). Some features of the current hepatic lesion (complex cystic appearance, enhancing wall, papillary projections and multiple internal septations, and internal hemorrhage) were similar to those of the primary ovarian GCT. In view of the patient's history, a primary diagnosis of hepatic metastatic recurrence of GCT was considered with a differential diagnosis of malignant transformation of a biliary cystadenoma. US-guided biopsy of the hepatic lesion was unsatisfactory. Hence, after discussion in a hepatobiliary multidisciplinary meeting, the decision was to proceed with a PET-CT scan, and it showed a low-level FDG uptake consistent with recurrence of the disease (Figure 5). It additionally showed a small peritoneal deposit.
FIGURE 3: MRI of the liver shows a complex cystic mass lesion in the left lobe of the liver

FIGURE 4: Coronal pre-operative MRI of pelvis done in 2012 shows a complex cystic mass lesion in the pelvis – primary granulosa cell tumor of the ovary
FIGURE 5: PET-CT showing mild radiotracer uptake by the left hepatic lobe complex cystic lesion (SUVmax 3.8) and the peritoneal nodule in the left side of the abdomen

PET-CT: positron emission tomography-computed tomography

The patient was admitted for surgical intervention on the third of March 2021 to resect the liver metastasis, and surgery started with diagnostic laparoscopy to rule out disseminated metastatic disease. The lesion was cystic in texture, measuring around 6X7 cm, and it was occupying segments III and IVb of the left liver lobe. Another small peritoneal nodule measuring around 2X2 cm was found in the right hepatorenal recess. After ruling out a disseminated metastatic disease by diagnostic laparoscopy, we proceeded with the resection by an inverted T-shaped incision and opening the abdominal wall in layers. Adhesiolysis was done around the left liver lobe and then a modified left hepatectomy was done after marking our resection line, which was to the left of the middle hepatic vein to resect segments II, III, and IVb with preservation of segment IVa. The peritoneal nodule was also excised from the hepatorenal recess. The patient had a smooth recovery postoperatively and was discharged on the fifth day of surgery with no significant complications. Histopathological examination of the cystic liver lesion (7.2 x 5 x 4.8 cm) revealed a cystic neoplasm composed of tumor cells exhibiting the characteristic features of granulosa cell tumor (Figures 6-7). The tumor nuclei had prominent grooves, imparting the classical "coffee bean" appearance (Figure 8). Whilst Call-Exner bodies are usually seen in the microfollicular architectural pattern of granulosa cell tumor, this feature was not noted in our case, as it had a diffuse architectural pattern.
FIGURE 6: Low power view revealing a cystic tumor (right) with blood clots within the cyst and background liver parenchyma (left) (H and E x2)

FIGURE 7: Macroscopic image of the cystic tumor, exhibiting marked hemorrhagic cystic degeneration
Immunohistochemically, the tumor was positive for inhibin (Figure 9), WT1 (Wilms' tumor suppressor gene 1), and calretinin (focal), confirming the histological diagnosis. Immunostains for cytokeratin CKAE1/AE3, CK7, and EMA were negative. Similar histological features were noted in the peritoneal nodule (2.2 x 1.5 cm), indicating another focus of metastatic granulosa cell tumor. Both metastatic foci were completely excised with adequate margins.
The patient has been following in the clinic for the past months with no new complaint. The gynecology multidisciplinary meeting plan is to follow the patient closely with AMH and inhibin, with no need for further hormonal or chemotherapy treatments.

**Discussion**

Ovarian cancer has the fifth highest mortality rate of all female cancers, representing 5-6% of cancer-related mortalities [8]. Overall, ovarian cancers originate from the epithelium surface in 85% of the cases while sex cord-stromal tumors represent 2-5% only, with GCT being the most common [9]. GCT frequently presents in multiparous women and can occur at any age but generally presents during the early postmenopausal period with a median age between 46 and 50 years in most series [10].

The two main subtypes of GCTs are adult GCTs (AGCTs) and juvenile GCTs (JGCTs) with AGCT as the most common [11]. GCT has never been reported to be originating from the liver previously and even liver metastasis from ovarian GCT is very rare, with only 18 reported cases (including this case) that underwent hepatectomy since the first description by Garcia et al. in 1996 [12-13].

Table 1 shows the epidemiology and clinical characteristics of the ovarian GCTs with liver metastasis who underwent hepatectomy, and we can notice that most of the liver metastases were diagnosed years after the primary tumor, which is the same in our patient. This finding concurs with the current literature suggesting that ovarian GCTs are commonly low-grade malignancies with a long, disease-free interval owing to the indolent nature of the disease. However, most patients must have prolonged follow-up and be aware of the fact that this type of tumor is well-known to have late recurrences with an incidence of 25-30% [20]. Hepatic metastases on the other hand are infrequently encountered, with an incidence of 5-6% of all GCT recurrences [18].

**FIGURE 9: Strong diffuse inhibit positivity (x 10)**
| Author               | Year of publication | No. of cases | Age at presentation for liver metastasis (years) | Symptoms at presentation | Other organs metastasis or invasion | Time from primary diagnosis to liver metastasis (months) | Time from liver metastasis to hepatectomy (months) |
|----------------------|---------------------|--------------|-------------------------------------------------|--------------------------|-----------------------------------|--------------------------------------------------------|--------------------------------------------------|
| Rodriguez Garcia et al. | 1996               | 1            | 62                                              | abdominal mass           | none                              | 72                                                      | 60                                               |
| Crew et al.          | 2005               | 1            | 58                                              | dyspnea                  | lung                              | 144                                                    | 120                                              |
| Lordan et al.        | 2007               | 1            | 64                                              | recurrent chest infection, abdominal pain | lung, peritoneal dissemination  | 180                                                    | 72                                               |
| Madhuri et al.       | 2010               | 3            | N/A                                            | dyspnea Abdominal pain (2 patients) | peritoneal dissemination        | 204/ 108/ 72                                            | 32 /12 /0                                        |
| Chua et al.          | 2011               | 2            | 46/ 31                                         | N/A                      | lung and peritoneal dissemination | 144/ 72                                                | 0/ 172                                            |
| Andreou et al.       | 2012               | 5            | N/A                                            | N/A                      | N/A                               | N/A                                                    | N/A                                               |
| Fujita et al.        | 2015               | 1            | 43                                              | abdominal distention and ascites | peritoneal dissemination       | 300                                                    | 0                                                |
| Yu et al.            | 2015               | 1            | 62                                              | abdominal pain           | jejunal metastasis              | 324                                                    | 0                                                |
| Antony et al.        | 2017               | 1            | 35                                              | abdominal pain and ascites | right diaphragm                  | 63                                                     | 50                                               |
| Koganezawa et al.    | 2020               | 1            | 76                                              | incidental               | right diaphragm                  | 264                                                    | 96                                               |
| Present case         | 2021               | 1            | 56                                              | abdominal pain           | peritoneal nodule               | 108                                                    | 0                                                |

**TABLE 1: Literature review: epidemiology and clinical characteristics of ovarian GCT patients with liver metastasis who underwent a hepatectomy**

* Not applicable

GCT: granulosa cell tumor

The longest recurrence-free survival period of granulosa cell tumor was reported by East et al., which was 40 years after the primary tumor, and occurred in the pelvis [21], while the longest recurrence-free survival period with hepatic metastasis was reported by Yu et al. and was 27 years post-primary tumor [22]. In our case, recurrence occurred nine years after treatment of the primary tumor.

The most common presenting symptom of ovarian GCT is vaginal bleeding (16.7-46%), followed by palpable abdominal mass (28.4%) and abdominal pain (17.6-44.3%) [23]. We can notice from Table 1 that most patients with ovarian GCT and liver metastasis were presenting with abdominal pain (33.3%) while the incidental discovery of the liver metastasis during follow-up for another pathology ensued in only one out of the 18 patients.

None of the patients were found to have a recurrence during their regular follow-up post-treatment of the primary tumor. This is related mainly to the fact that those patients have already been lost to follow-up due to tumor recurrence years after primary presentation with a recurrence-free survival mean of 158 months (13 years) (Table 1).

As for diagnosis, the most used tumor markers for GCT detection and recurrence are AMH and inhibin (mainly Inhibin B) [22]. In a partially prospective cohort study, Färkkilä et al. collected data of 125 patients with 10.5 years as a median follow-up to evaluate the efficiency of both AMH and inhibin B as tumor.
markers for GCT. AMH has been shown to be a specific circulating marker for GCT. Its diagnostic performance appears to be effective for primary and recurrent GCT with 92% sensitivity and 81% specificity [6].

With respect to inhibin as a tumor marker, there is two main subtypes (inhibin A and B). Inhibin B is the main form secreted by granulosa cell tumors, and it is more accurate in reflecting disease status than inhibin A. Therefore, measurement of serum inhibin B level is preferred for the follow-up of GCT [22]. This finding is particularly accurate in our case, as inhibin A was normal in this patient after recurrence while the inhibin B value was elevated. Serum estrogen and CA 125 concentrations have been used to detect primary tumor and recurrences; however, a consistent correlation could not be confirmed between their levels and tumor activity [10,24].

CT scan was the main modality for follow-up and detection of recurrence preoperatively as we can notice in Table 2. Although Koganezawa et al. performed PET-CT during the evaluation of his patient, no significant FDG uptake could be found in the hepatic tumor or other parts of the body. Hence, the tumor was suspected to be a liver hemangiosarcoma [12]. To our knowledge, this is the first report of preoperative PET-CT diagnosis of hepatic metastatic recurrence of ovarian GCT. Also, ours is the first report showing comparative MRI features of the hepatic metastasis and the primary GCT.

| Author           | Follow-up tumor markers | Imaging modality used       | Type of liver resection | Combined resection of other organs | recurrence |
|------------------|-------------------------|-----------------------------|-------------------------|-----------------------------------|------------|
| [13] Rodriguez Garcia et al. | N/A*                    | US, CT scan               | Right hepatectomy       | No                                | No         |
| [14] Crew et al.     | Estradiol, inhibin      | CT scan                    | Partial hepatectomy     | Yes                               | Yes        |
| [15] Lordan et al.   | N/A                     | CT scan, MRI               | Extended right hepatectomy | Yes                               | Yes        |
| [4] Madhuri et al.   | N/A                     | N/A                        | Partial hepatectomy     | Yes                               | No         |
| [16] Chua et al.     | N/A                     | N/A                        | Partial, right hepatectomy | Yes                               | 1 Yes 1 / No |
| [17] Andreou et al.  | N/A                     | N/A                        | N/A                     | N/A                               | N/A        |
| [3] Fujita et al.    | Estradiol, CA 125**     | US, CT scan, MRI           | Right hepatectomy       | Yes                               | Yes        |
| [18] Yu et al.       | AFP***                   | CT scan                    | Central bisectionectomy | No                                | No         |
| [19] Antony et al.   | CA 125, AFP              | CT scan                    | Partial, right hepatectomy | Yes                               | No         |
| [12] Koganezawa et al.| AFP                     | CT scan, MRI, PET-CT       | Right trisectionectomy  | No                                | No         |
| Present case        | Estradiol, inhibin, AMH****, AFP | US, CT scan, MRI, PET-CT (could not appreciate recurrence) | Left hepatectomy | Yes                               | Under follow up |

TABLE 2: Literature review: diagnosis modality and surgical intervention type of ovarian GCT patients with liver metastasis

* Not applicable; ** Cancer antigen 125; *** Alpha-fetoprotein; **** Anti-Mullerian hormone

GCT: granulosa cell tumor

Concerning treatment, primary surgery is the standard treatment for both types of GCTs. It is generally curative in most patients due to the early stage and unilateral involvement [22]. Typically, surgery should comprise of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection is of limited value, mainly in early-stage disease [22]. In advanced disease patients (stages II-IV), cytoreductive surgery should
be done to resect as much as possible tumor load and metastases [25]. Many authors reported that removal of the remaining disease can significantly enhance a patient’s postoperative quality of life and recurrence-free survival [25]. The role of adjuvant chemo and radiotherapy is mainly for patients with advanced or recurrent disease. In early-stage disease, their efficiency is still unclear as its utilization did not affect disease-free survival [26].

In our patient left hepatectomy was done as liver metastasis was expected to be the only form of GCT recurrence. No further adjuvant therapy was offered for the patient after treating this recurrence and so far, no recurrence of liver metastasis was observed.

Conclusions

GCT recurrence as liver metastasis is an extremely rare finding that can be encountered late post-resection of the primary tumor. Inhibin B and AMH are the most accurate tumor markers for recurrence detection. Variable imaging modalities could be used for diagnosis, including MRI and PET-CT. Surgical resection for advanced disease and disease recurrence to remove the remaining disease can enhance the patient’s postoperative quality of life and recurrence-free survival.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Review Board (IRB) and Medical Research Center (MRC), Hamad Medical Corporation issued approval MRC-04-21-311. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH: Classification of tumors of the ovary. WHO Classification of Tumours of Female Reproductive Organs. WHO Classification of Tumours, 4th Edition, Volume 6. IARC, Lyon; 2014. 6:44-56.
2. Colombbo N, Parma G, Zanagnolo V, Inzinga A: Management of ovarian stromal cell tumors. J Clin Oncol. 2007, 25:2944-51. 10.1200/JCO.2007.11.1005
3. Fujita F, Eguchi S, Takatsuki M, et al.: A recurrent granulosa cell tumor of the ovary 25 years after the initial diagnosis: a case report. Int J Surg Case Rep. 2015, 12:7-10.
4. Madhuri TK, Butler-Manuel S, Kananija N, Tailor A: Liver resection for metastases arising from recurrent granulosa cell tumor of the ovary--a case series. Eur J Gynaecol Oncol. 2010, 31:542-4.
5. La Marca A, Volpe A: The Anti-Müllerian hormone and ovarian cancer. Hum Reprod Update. 2007, 13:265-73. 10.1093/humupd/dml060
6. Färkkälä A, Koskela S, Bryk S, et al.: The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors—a comparative study with inhibin B. Int J Cancer. 2015, 137:1661-71. 10.1002/ijc.29532
7. Mom CH, Engelen MJ, Willems PH, Gietema JA, ten Hoor KA, de Vries EG, van der Zee AG: Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol. 2007, 105:565-72. 10.1016/j.ygyno.2006.12.054
8. Redman C, Duffy S, Dobson C: Improving early detection of ovarian cancer. Practitioner. 2011, 255:27-50, 3.
9. Pectasides D, Pectasides E, Psyrri A: The role of adjuvant chemo and radiotherapy is mainly for patients with advanced or recurrent disease. In early-stage disease, their efficiency is still unclear as its utilization did not affect disease-free survival. [26].
10. Lee IH, Choi CH, Hong DG, et al.: Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. J Gynecol Oncol. 2011, 22:188-95. 10.3802/jgo.2011.22.3.188
11. Yesilyurt H, Tokmak A, Guezl AI, Simsek HS, Erkaya S, Gungor T: Parameters for predicting granulosa cell tumor of the ovary: a single center retrospective comparative study. Asian Pac J Cancer Prev. 2014, 15:8447-50. 10.7314/apjcp.2014.15.19.8447
12. Koganemura I, Tomita K, Nakagawa M, et al.: Right trisectionectomy for liver metastasis of granulosa cell tumor: a case report and literature review. Surg Case Rep. 2020, 6:125. 10.1186/s40792-020-00880-5
13. Rodríguez García JJ, González González JJ, García Flórez LJ, Floriano Rodríguez P, Martínez Rodríguez E: Hepatic metastases of granulosa cells tumour of the ovary. HPB Surg. 1996, 10:55-7. 10.1155/1996/13452
14. Crew KD, Smith MH, Smith DH, Tiersten AD, Fein NM, Hershman DL: Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol. 2005, 96:235-40. 10.1016/j.ygyno.2004.09.023
15. Lordan JT, Jones RL, Karanjia ND, Butler-Manuel S: Debulking hepatectomy for an unusual case of a grade 1 stage 1 granulosa cell tumour of the ovary with late metastases. Oncology. 2007, 72:145-4. 10.1159/000111140
16. Chua TC, Iyer NG, Soo KC: Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary. J Gynecol Oncol. 2011, 22:214-7. 10.5822/jgo.2011.22.3.214
17. Andreou A, Brouquet A, Bharathy KG, et al.: Liver resection for liver metastases from nondigestive
endocrine cancer: extrahepatic disease burden defines outcome. Surgery. 2012, 151:851-9. 10.1016/j.surg.2011.12.025

18. Yu S, Zhou X, Hou B, Tang B, Hu J, He S: Metastasis of the liver with a granulosa cell tumor of the ovary: a case report. Oncol Lett. 2015, 9:816-8. 10.3892/ol.2014.2784

19. Antony MA, Pavithran K, Vijaykumar DK, Sudheer OV: Long-term survival following repeat liver resections in metastatic ovarian granulosa cell tumor: case report with review of the literature. South Asian J Cancer. 2017, 6:87-8. 10.4103/2278-330X.208852

20. Hasiakos D, Papakonstantinou K, Karvouni E, Fotiou S: Recurrence of granulosa cell tumor 25 years after initial diagnosis. Report of a case and review of the literature. Eur J Gynaecol Oncol. 2008, 29:86-8.

21. Hauspy J, Beiner ME, Harley I, et al.: Role of adjuvant radiotherapy in granulosa cell tumors of the ovary. Int J Radiat Oncol Biol Phys. 2011, 79:770-4. 10.1016/j.ijrobp.2009.12.005

22. Levin G, Zigron R, Hai-Yahya R, Matan LS, Rottemstreich A: Granulosa cell tumor of ovary: a systematic review of recent evidence. Eur J Obstet Gynecol Reprod Biol. 2018, 225:57-61. 10.1016/j.ejogrb.2018.04.002

23. East N, Alobaid A, Goffin F, Ouallouche K, Gauthier P: Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can. 2005, 27:563-4. 10.1016/s1701-2163(16)30464-9

24. Lappöhn RE, Burger HG, Bouma J, Bargah M, Krans M: Inhibin as a marker for granulosa cell tumor. Acta Obstet Gynecol Scand Suppl. 1992, 155:61-5. 10.1111/j.1600-0412.1992.tb00008.x

25. Rinne N, Farthing A, Borley J: Fertility sparing surgery in advanced and recurrent granulosa cell tumours of the ovary. J Obstet Gynaecol. 2018, 38:143-5. 10.1080/01443615.2017.1532579

26. Park JY, Jin KL, Kim DY, et al.: Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2012, 125:80-6. 10.1016/j.ygyno.2011.12.442